NASDAQ: PPBT - Purple Biotech Ltd.

Rentabilidade por seis meses: +655.24%
Setor: Healthcare

Cronograma de promoção Purple Biotech Ltd.


Sobre a empresa

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.

Mais detalhes
Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

EBITDA -0.0076
EV/EBITDA 0.3461
IPO date 2015-11-20
ISIN US74638P1093
Industry Biotechnology
P/BV 0.1398
P/S 1.52
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.001
Сайт https://purple-biotech.com
Цена ао 0.6218
Число акций ао 0.02462 млрд
Alteração de preço por dia: -8.16% (5.88)
Alteração de preço por semana: +4.45% (5.17)
Alteração de preço por mês: +1 100% (0.45)
Alteração de preço em 3 meses: +1 488.24% (0.34)
Mudança de preço em seis meses: +655.24% (0.715)
Mudança de preço por ano: +429.41% (1.02)
Mudança de preço em 3 anos: +10.66% (4.88)
Mudança de preço em 5 anos: +529.37% (0.858)
Mudança de preço desde o início do ano: +237.5% (1.6)

Subestimação

Nome Significado Nota
P/S -31.39 0
P/BV 11.78 1
P/E 0 0
EV/EBITDA -17.66 0
Total: 1.63

Eficiência

Nome Significado Nota
ROA, % -44.87 0
ROE, % -58.12 0
Total: 1.67

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0159 10
Total: 9.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -191 0
Rentabilidade Ebitda, % 190.42 10
Rentabilidade EPS, % -74.37 0
Total: 6

Instituições Volume Compartilhar, %
Armistice Capital, LLC 1882173 7.26
Wuxi Apptec Co., Ltd. 194139 0.75
Kingswood Wealth Advisors, LLC 175100 0.68
Morgan Stanley 86513 0.33
Venture Visionary Partners LLC 15553 0.06
Wealth Advisors of Iowa, LLC 14270 0.06
XTX Topco Ltd 13561 0.05
Geode Capital Management, LLC 12666 0.05
Citadel Advisors Llc 11777 0.05
Raymond James & Associates, Inc. 11000 0.04



Supervisor Cargo Pagamento Ano de nascimento
Dr. Michael Schickler Ph.D. Head of Clinical & Regulatory Affairs 264.98k 1958 (66 anos)
Mr. Ido Morpurgo B.Sc., L.L.M. Vice President of Operations N/A 1972 (52 ano)
Mr. Gil Efron CPA, M.A. Chief Executive Officer 1966 (58 anos)
Mr. Lior Fhima CPA, M.B.A. Chief Financial Officer 1977 (47 anos)

Endereço: Israel, Rehovot, 4 Oppenheimer Street - abrir no Google Maps, abrir mapas Yandex
Site: https://purple-biotech.com